Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	32.79	24.46	18.89	30.37	22.52
Short-Term Investments	24.15	33.75	106.08	26.95	75.56
Cash & Cash Equivalents	56.93	58.21	124.97	57.33	98.08
Cash Growth	-2.19%	-53.42%	117.99%	-41.55%	-23.70%
Receivables	30.55	40.32	15.47	15.97	10.11
Inventory	5.52	9.12	6.62	1.64	1.35
Other Current Assets	6.26	8.26	7.41	14.05	9.46
Total Current Assets	99.27	115.9	154.47	88.98	119.01
Property, Plant & Equipment	1.03	2.79	11.89	20.57	27.87
Goodwill and Intangibles	13.88	14.95	0	0	0
Other Long-Term Assets	3.06	0.64	0.97	0.82	0.7
Total Long-Term Assets	17.96	18.38	12.86	21.4	28.56
Total Assets	117.23	134.28	167.33	110.38	147.57
Accounts Payable	7.14	22.51	3.8	3.71	4.15
Deferred Revenue	17.04	13.51	10.51	3.02	26.69
Current Debt	7.92	1.13	9.89	8.62	7.27
Other Current Liabilities	21.17	28.06	39.36	25.5	20.1
Total Current Liabilities	53.27	65.21	63.55	40.84	58.21
Long-Term Debt	52.66	40.42	20.67	30.47	29.04
Other Long-Term Liabilities	39.94	42.26	52.73	5.05	6.5
Total Long-Term Liabilities	92.6	82.68	73.4	35.51	35.54
Total Liabilities	145.87	147.9	136.95	76.35	93.75
Total Debt	60.58	41.55	30.57	39.09	36.31
Debt Growth	45.79%	35.95%	-21.80%	7.64%	-
Retained Earnings	-1,407.55	-1,382.46	-1,323.89	-1,305.97	-1,276.23
Comprehensive Income	0.01	-0.15	-0.1	-0	0.02
Shareholders' Equity	-28.64	-13.62	30.37	34.03	53.82
Net Cash / Debt	-3.65	16.65	94.4	18.24	61.77
Net Cash / Debt Growth	-	-82.36%	417.55%	-70.47%	-51.95%
Net Cash Per Share	-0.21	0.97	5.54	1.08	3.69
Working Capital	46	50.69	90.91	48.14	60.79
Book Value Per Share	-1.65	-0.79	1.78	2.02	3.21

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).